Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease.

TÖRÜNER M., Erkan Ö., Soykan I., Bozdayi M., Çetinkaya H., Yurdaydin C., ...More

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.15, no.4, pp.250-2, 2004 (Scopus, TRDizin)

Abstract

Background/aims: Thromboembolic events are more common in patients with inflammatory bowel disease than in the normal population; however, the reason for the increased prevalence is not clear. The aim of this study was to evaluate the prevalence of factor V Leiden, prothrombin G20210A and methylene tetrahydrofolate reductase (MTHFR) gene mutations in IBD patients followed in our outpatient clinic. Methods: Thirty-four patients with ulcerative colitis and 28 patients with Crohn's disease and 80 healthy controls were included in the study. No patient had a history of previous thromboembolism. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations were studied. Results: Heterozygote factor V Leiden mutation was found in five (6.25%) control patients and in two (3.2%) IBD patients. Heterozygote MTHFR mutation was obtained in seven (11.3%) IBD patients and in five (6.25%) controls. Heterozygote prothrombin G20210A mutation was found in two (2.5%) and homozygote MTHFR mutation in one (1.25%) control patient. There was no statistical difference between the IBD group and healthy controls. Conclusions: Genetic mutations that could increase the thrombosis risk were not found to be different in IBD versus the normal population in our study.